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ARTICLE
m6A mRNA demethylase FTO regulates melanoma
tumorigenicity and response to anti-PD-1 blockade
Seungwon Yang 1,9, Jiangbo Wei2,9, Yan-Hong Cui1,9, Gayoung Park3, Palak Shah 1,4, Yu Deng 1,5,
Andrew E. Aplin 6,7, Zhike Lu2, Seungmin Hwang 3, Chuan He 2,8,10 & Yu-Ying He 1,10
Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-
methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein
(FTO) increases melanoma growth and decreases response to anti-PD-1 blockade immu-
notherapy. FTO level is increased in human melanoma and enhances melanoma tumor-
igenesis in mice. FTO is induced by metabolic starvation stress through the autophagy and
NF-κB pathway. Knockdown of FTO increases m6A methylation in the critical protumorigenic
melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and SOX10, leading to
increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes
melanoma cells to interferon gamma (IFNγ) and sensitizes melanoma to anti-PD-1 treatment
in mice, depending on adaptive immunity. Our ﬁndings demonstrate a crucial role of FTO as
an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and
suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce the
resistance to immunotherapy in melanoma.
https://doi.org/10.1038/s41467-019-10669-0 OPEN
1 Department of Medicine, Section of Dermatology, University of Chicago, Chicago, IL 60637, USA. 2 Departments of Chemistry, Department of Biochemistry
and Molecular Biology, Institute for Biophysical Dynamics, University of Chicago, Chicago, IL 60637, USA. 3 Department of Pathology, University of Chicago,
Chicago, IL 60637, USA. 4 Committee on Molecular Pathogenesis and Molecular Medicine, University of Chicago, Chicago, IL 60637, USA. 5Department of
Environmental Health, School of Public Health, China Medical University, Shenyang, Laoning 110122, China. 6 Department of Cancer Biology, Thomas
Jefferson University, Philadelphia, PA 19107, USA. 7 Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA. 8Howard
Hughes Medical Institute, University of Chicago, Chicago, IL 60637, USA. 9These authors contributed equally: Seungwon Yang, Jiangbo Wei, Yan-Hong Cui.
10These authors jointly supervised this work: Chuan He, Yu-Ying He. Correspondence and requests for materials should be addressed to
Y.-Y.H. (email: yyhe@medicine.bsd.uchicago.edu) or to C.H. (email: chuanhe@uchicago.edu)
NATURE COMMUNICATIONS |         (2019) 10:2782 | https://doi.org/10.1038/s41467-019-10669-0 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Melanoma is one of the most deadly and therapy-resistanthuman cancers in the United States1. The incidence ofmelanoma continues to rise at an alarming rate each
year, faster than any of the other common cancers2. In the past
decades, tremendous progress has been made in elucidating the
mechanism of melanoma development at the molecular, cellular
and organismal levels1. Both genetic, including mutations in
oncogenes and tumor suppressor genes, and epigenetic
mechanisms, including DNA methylation, microRNAs, and other
non-coding RNAs, have been demonstrated to play critical roles
in melanoma pathogenesis1,3–5. In particular, the discoveries of
BRAF mutations and their functions in most melanomas have led
to the development of molecular therapy targeting the mutant
BRAF1. However, the majority of the patients treated with an
inhibitor of mutant BRAF eventually suffer continuous disease
progression6. Recent breakthroughs in immunotherapy, including
anti-PD-1 checkpoint blockade therapy, have beneﬁtted a grow-
ing number of melanoma patients7–9. Still, more than half of
these patients do not show a durable response to immunotherapy.
Multiple mechanisms, such as driver mutations, epigenetic
mechanisms, tumor plasticity, and immunosuppression, may
cooperate to maintain the melanoma phenotype and mediate
resistance to therapies, including immunotherapy10,11, which
makes targeting a single pathway less effective. Our under-
standing of the molecular mechanisms for melanoma develop-
ment and therapeutic response is still limited.
An emerging molecular mechanism regulating gene expression
at the post-transcription level is N6-methyladenosine (m6A) RNA
methylation. m6A RNA methylation is the most prominent
chemical modiﬁcation found in messenger RNA (mRNA) and
non-coding RNA in eukaryotic cells12–15. Recently, the ﬁrst m6A
demethylase FTO was discovered, suggesting that m6A RNA
methylation is reversible and dynamic and may have crucial
physiological and pathological functions16. Subsequently, two
studies independently mapped the transcriptome-wide m6A dis-
tribution17,18. These studies also suggest that, similar to the
reversible epigenetic modiﬁcations to DNA and histone, post-
transcriptional methylation of adenosines in RNA provides an
epitranscriptomic layer of regulation that may control mRNA fate
and gene expression.
In the past several years, compelling evidence has demonstrated
that m6A methylation plays critical roles in controlling RNA
metabolism and function in physiological processes and stress
response. m6A modiﬁcation regulates development, stem cell
homeostasis, response to stresses such as heat-shock and genotoxic
damage, and control of the circadian clock19–22. m6A modiﬁcation
regulates RNA fate and such functions as mRNA stability, nuclear
processing, transport, localization, translation, primary microRNA
processing, and RNA-protein interactions23–28. m6A modulators
have been shown to play important roles in several cancers by
regulating cancer-type-speciﬁc target genes and functions19,20,
suggesting the unique regulatory and functional signiﬁcance of
the intrinsic m6A mRNA modiﬁcations and their regulators in
different cancers. Recent work has also suggested that the genetic
variations of FTO are associated with increased melanoma risk
in humans29,30. The association of these FTO variations in exon
8 with melanoma risk seems to be independent of body mass
index (BMI)29,30. As the ﬁrst m6A demethylase identiﬁed, FTO has
been show to act as an oncogenic factor in leukemia31,32 and
glioblastoma33. However, the role of FTO as an m6A eraser in
melanoma pathogenesis and response to anti-melanoma therapies
remains poorly understood.
Here we report that the m6A demethylase FTO regulates
melanoma growth and mediates melanoma resistance to anti-PD-
1 antibody in vitro and in vivo. Our results identify a unique
FTO-mediated and m6A-mediated mechanism in promoting
melanoma tumorigenesis and resistance to anti-PD-1 blockade,
and suggest that the combination of FTO inhibition with anti-
PD-1 blockade may reduce resistance and improve the anti-
melanoma response.
Results
FTO as a protumorigenic factor in melanoma. To determine the
role of FTO in human melanoma, we ﬁrst analyzed FTO protein
levels speciﬁcally in the melanocytes of normal human skin and
malignant melanoma samples using immunoﬂuorescence. We
used MART1 immunoﬂuorescence co-staining (Green) to speci-
ﬁcally identify melanocytes in normal skin and melanoma cells
(Fig. 1a). FTO (Red) was low in epidermal melanocytes in normal
skin (n= 16), while it was signiﬁcantly increased in all diagnoses
of melanoma, including metastasis (n= 64), primary melanoma
(n= 36), and melanoma at stages I–IV (n= 65) (Fig. 1a, b).
There was no signiﬁcant difference in FTO levels between dif-
ferent diagnosis groups of melanomas except between Stage I and
IV. Next, we determined the FTO protein levels in normal human
epidermal melanocytes (NHEM) and a panel of melanoma cell
lines. FTO remained unchanged in WM35 (BRAF mutation,
Human) cells (Fig. 1c). However, it was up-regulated in six of the
tested cell lines, particularly in Mel624 (BRAF mutation, Human)
and B16F10 (BRAF wild-type, Mouse) cells, two aggressive model
melanoma cell lines, as well as WM115 (BRAF mutation,
Human), WM793 (BRAF mutation, Human), WM3670 (BRAF
and NRAS mutation, Human), and CHL-1 (BRAF and NRAS
wild-type, Human) (Fig. 1c). These results demonstrate that FTO
is upregulated in human melanoma samples and multiple mela-
noma cell lines, suggesting a protumorigenic role of FTO in
melanoma development.
To determine the biological function of FTO in melanoma
cells, we performed both gain- and loss-of-function studies in
melanoma cells (Fig. 2a). Knockdown of FTO in FTO-high
Mel624, CHL-1, and B16F10 cells decreased cell growth/
proliferation, migration, invasion, and cell viability in cells placed
in suspension (Fig. 2b–e, and Supplementary Fig. 1a–n). In
addition, FTO knockdown also decreased cell invasiveness in 3D
culture with Matrigel and colony formation in soft agar,
respectively (S1O-S1S). Overexpression of FTO markedly
increased cell proliferation, cell migration, invasion, and cell
viability in cells in suspension (Fig. 2b–e, and Supplementary
Fig. 1d) in WM35 with an FTO protein level similar to NHEM
(Fig. 1c). To elucidate the role of FTO in melanoma pathogenesis
in vivo, we performed xenograft and syngeneic melanoma
tumorigenesis assays. Knockdown of FTO markedly reduced
tumor volume and tumor growth in both Mel624 and CHL-1
cells in immunocompromised nude mice, and in B16F10 cells in
immunocompetent C57BL/6 mice (Fig. 2f, g, and Supplementary
Fig. 2a–j). Furthermore, forced overexpression of FTO in WM35
induced tumor growth in immunocompromised nude mice
(Fig. 2f, g, and Supplementary Fig. 2d). These ﬁndings suggest
that FTO is required for the malignant traits of melanoma cells
in vitro and plays a protumorigenic role in melanoma tumor
growth in vivo.
Role of m6A in FTO function in melanoma cells. To examine
the role of FTO in m6A regulation, we investigated the effect of
FTO knockdown on m6A levels in mRNA16,34. Knockdown of
FTO increased m6A levels in both total RNA and puriﬁed mRNA
in both Mel624 and B16F10 cells (Fig. 3a–d). To determine the
role of m6A in melanoma cell function, we performed gain-of-
function tests of the m6A writers METTL3 (Methyltransferase
Like 3) and METTL14 (Methyltransferase Like 14). Forced
overexpression of METTL3 and METTL14 increased the
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total m6A level and decreased cell growth/proliferation
(Fig. 3e–g), migration, and invasion (Fig. 3h, i, and Supplemen-
tary Fig. 3a, b). Furthermore, knockdown of METTL3 and
METTL14 prevented the effect of FTO knockdown on cell
growth/proliferation, migration, invasion, and cell viability in
melanoma cells in suspension (Fig. 3j–m, and Supplementary
Figs. 3e–j, 4a–f). The opposite was also true. Overexpression of
METTL3 and METTL14 prevented the effect of FTO over-
expression on these malignant traits (Supplementary Fig. 4g–l).
These ﬁndings indicate that m6A modiﬁcations in RNA reduce
melanoma cell proliferation and cell viability, suggesting a tumor-
suppressive role of m6A in melanoma.
Identiﬁcation of potential target genes of FTO in melanoma.
We next used both candidate and unbiased screening approaches
to determine the potential mRNA targets of FTO in its
melanoma-promoting function (Fig. 4a). First, we started with a
candidate approach, focusing on the genes that are known to be
associated with melanoma growth and in particular response to
immunotherapy, including known melanoma-promoting genes
PD-1 (PDCD1)35, PD-L1 (CD274)11,36, and CD4737–39. All three
genes were expressed in Mel624 cells. We found that serum
starvation induced the expression of FTO, PD-1 (PDCD1), and
CD47, but not PD-L1 (CD274) (Supplementary Fig. 5a). FTO
knockdown signiﬁcantly decreased PD-1 (PDCD1) expression,
but had no effect on PD-L1 (CD274) or CD47 (Fig. 4b). These
data suggested that PD-1 is a potential FTO target gene in mel-
anoma. Second, we performed microarray analysis of gene
expression in MEL624 cells with or without FTO knockdown to
determine transcriptome-wide changes upon FTO knockdown.
We identiﬁed 106 genes that were signiﬁcantly altered by FTO
knockdown (Fig. 4a). Third, we used m6A- seq in combinaton
with RNA-seq to identify more than 1000 potential
transcriptome-wide m6A-modiﬁedgene targets for FTO (Fig. 4a),
including the melanoma-promoting genes CXCR4 and SOX10.
m6A peaks detected in poly(A)+-enriched RNAs showed repro-
ducible patterns of methylation (Supplementary Fig. 5b). FTO
knockdown increased m6A enrichment in 5′UTR and 3′UTR,
while it had little effect on the CDS region (Fig. 4c), and altered
total peak distribution and unique peak distribution (Fig. 4d).
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FTO knockdown cells also showed an increased number of
common m6A genes (Fig. 4e) and fewer m6A peaks (Supple-
mentary Fig. 5c), likely due to the degradation of m6A-modiﬁed
mRNAs. Sequence analysis of m6A peaks showed the previously
identiﬁed m6A target sites (GGACU)17 (Fig. 4f). However, PD-1
(PDCD-1) was undetectable in either microarray or RNA-seq
analysis (Supplementary Fig. 5d), possibly due to the limitations
of these assays. m6A IP seq analysis showed that FTO knockdown
increased the m6A levels in the transcripts of CXCR4 and SXO10
(Supplementary Fig. 5e, f). Next, we validated a set of
downregulated genes (PD-1 (PDCD1), CXCR4, SOX10,
ANGPTL2, CTSV, FCMR, NOP16, and RAB40), and upregulated
genes (CDKN1A) upon FTO knockdown (Fig. 4g, and Supple-
mentary Fig. 5g–i). Consistently, m6A IP qPCR analysis showed
that FTO knockdown increased the m6A levels in the transcripts
of PD-1 (PDCD1), CXCR4, SOX10, CTSV, and NOP16 (Fig. 4h),
suggesting these genes as potential targets of FTO.
Identiﬁcation of functionally critical target genes of FTO.
Among the genes identiﬁed above, PD-1 has been shown to be
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Fig. 2 Effect of FTO knockdown or forced FTO expression in melanoma cells. a Conﬁrmation of knockdown or forced expression of FTO in Mel624, CHL-1,
B16F10, and WM35 by immunoblot analysis. b Cell proliferation assay in Mel624, CHL-1, B16F10, and WM35 with shNC (negative control), shFTO (FTO
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expressed in some melanoma cells and act as an intrinsic pro-
tumorigenic factor to promote melanoma tumor growth35. It
activates the downstream of mTOR signaling35, demonstrating a
critical intrinsic role of PD-1 in melanoma. In addition, PD-1 has
been successfully targeted in immune cells for cancer immu-
notherapy36. Therefore understanding the regulation of PD-1
may have a broader impact on cancer biology and immu-
notherapy response in melanoma. In addition, CXCR4 and
SOX10 are critical melanoma-promoting genes40–42. Thus we
decided to focus on investigating whether PD-1, CXCR4, and
SOX10 act as crucial targets of FTO. Additional shRNAs targeting
FTO conﬁrmed that FTO regulates the expression of PD-1
(PDCD1), CXCR4, and SOX10 (Fig. 5a, and Supplementary
Fig. 6a–c). Knockdown of FTO reduced the protein levels of
PD-1, CXCR4, and SOX10, as well as the phosphorylation of
p70s6K, a substrate of mTOR activation (Fig. 5a, and Supple-
mentary Fig. 6a–c). The opposite was also true. Forced over-
expression of FTO increased the protein and mRNA levels of
these genes as well as the phosphorylation of p70s6K (Fig. 5b, and
Supplementary Fig. 6d). Furthermore, forced overexpression of
wild-type (WT) FTO increased the mRNA and protein levels of
PD-1 (PDCD1), CXCR4, and SOX10, and cell proliferation,
whereas demethylase-inactive mutants16 had no effect (Supple-
mentary Fig. 6e–h). These ﬁndings indicate that FTO is respon-
sible for promoting the expression of melanoma-intrinsic PD-1,
CXCR4, and SOX10.
Next we investigated whether these melanoma-promoting
genes are responsible for FTO’s function. Forced overexpression
of PD-1 (PDCD1) in FTO knockdown cells increased phosphor-
ylation of p70s6K (Fig. 5c), accompanied by signiﬁcantly
increased cell growth/proliferation (Fig. 5d) and migration
(Fig. 5e, and Supplementary Fig. 7a). Similarly, forced over-
expression of CXCR4 and SOX10 in FTO knockdown cells
signiﬁcantly increased cell growth/proliferation and migration
(Fig. 5f–i, and Supplementary Fig. 7b–e). These results demon-
strate that PD-1, CXCR4, and SOX10 are critical downstream
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targets of FTO responsible for its function in melanoma. Indeed,
all melanoma cell lines showed increased PD-1 protein levels as
compared with normal melanocytes (Supplementary Fig. 7f). PD-
1 (PDCD1) mRNA expression is positively associated with FTO
expression in melanoma (Supplementary Fig. 7g, h). In addition,
we found a positive association between FTO and PD-1 protein
levels in Mel624 cells (Supplementary Fig. 7i, j) and human
melanoma tissue (Supplementary Fig. 7k–m).
To determine whether regulation of these melanoma-
promoting genes by FTO is m6A-dependent, we assessed the
role of m6A by knocking down the m6A methyltransferases
METTL3 and METTL14 (Supplementary Fig. 8a–c). In FTO
knockdown cells, subsequent knockdown of both METTL3 and
METTL14 signiﬁcantly increased the mRNA levels of PD-1
(PDCD1), CXCR4, SOX10, CTSV2, and NOP16 (Fig. 5j–n, and
Supplementary Figs. 8a–d, 9a, b), and the protein levels of PD-1,
CXCR4, and SOX10 (Fig. 5o), respectively, to a level similar to
that in the control cells (Fig. 5j–o). These ﬁndings demonstrate
that FTO regulates the expression of its target genes via m6A
RNA modiﬁcation and its demethylase activity.
Role of YTHDF2 in FTO’s function in melanoma. The function
of m6A in regulating gene expression is executed mostly
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through the readers, including YTH domain-containing family
proteins in mammalian cells17. FTO knockdown did not affect
the expression of critical m6A regulators (Fig. 6a). To determine
how m6A RNA methylation regulates gene expression, we
analyzed the role of YTHDF1-3. Knockdown of YTHDF1 or
YTHDF3 had no effect on the mRNA levels of PD-1 (PDCD1),
CXCR4, or SOX10 in control and FTO-knockdown cells.
However, knockdown of YTHDF2 signiﬁcantly increased the
mRNA levels of all three genes in both control and FTO-
knockdown cells (Fig. 6b–d, and Supplementary Fig. 10a–c).
Moreover, knockdown of FTO decreased the mRNA stability of
PD-1 (PDCD1), CXCR4, and SOX10 (Fig. 6e–g). Knockdown of
YTHDF2 increased the mRNA stability of PD-1 (PDCD1),
CXCR4, and SOX10 in shFTO cells (Fig. 6h–j). Consistently,
knockdown of YTHDF2 increased, while forced overexpression
of YTHDF2 decreased, cell proliferation and migration in
melanoma cells in vitro (Fig. 6k, l, and Supplementary
Fig. 10d–f) as well as tumor growth in vivo (Fig. 6m, and
Supplementary Fig. 10g, h), supporting a tumor suppressor role
for YTHDF2. These ﬁndings indicate that YTHDF2-mediated
RNA decay controls the expression of the FTO target genes in
melanoma cells.
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FTO expression is induced by metabolic stress. To investigate
potential pathways by which FTO is upregulated in melanoma
cells, we analyzed the role of metabolic stress, since cancer cells
acquire adaptive capabilities to survive and grow under metabolic
stress. We found that metabolic stress conditions, such as low
serum (0.2% FBS) or model starvation medium (Hank’s Balanced
Salt Solution, HBSS, lacking serum, amino acids and glucose)
increased the expression of FTO and PD-1 (PDCD1) at the
mRNA (Fig. 7a, and Supplementary Fig. 5a) and protein levels
(Fig. 7b, and Supplementary Fig. 11a, b). Consistently, HBSS
decreased the m6A level (Fig. 7c). Since these conditions are
also known to induce autophagy (Fig. 7b, and Supplementary
Fig. 11a, b), we reasoned that FTO induction by metabolic
stress is mediated through the autophagy pathway. Indeed,
knockdown of the autophagy essential genes ATG5 or ATG7
reduced starvation-induced FTO and PD-1 (PDCD1) expression,
as well as NF-κB activity (Fig. 7d, e). Knockdown of
FTO decreased PD-1 (PDCD1) expression (Fig. 7f). Knockdown
of the NF-κB subunit p65 (RELA) markedly reduced the induc-
tion of FTO and PD-1 (PDCD1) by metabolic stress (Fig. 7g).
These results demonstrate that FTO and PD-1 (PDCD1) are
induced by metabolic stress through the autophagy and NF-κB
pathways.
Role of FTO on anti-PD-1 blockade and IFNγ. Although
immunotherapy has been effective in producing long-lasting
therapeutic effects on several aggressive cancers in a subset of
patients7–9, understanding the mechanism of resistance is critical
to broaden the clinical application of immunotherapy for patients
with advanced cancers11. Since FTO promotes melanoma
tumorigenicity and regulates the expression of tumor-promoting
melanoma cell-intrinsic PD-1 as well as CXCR4 and SOX10, we
reasoned that FTO may also regulate the response of melanoma
to immunotherapy. To determine whether FTO inhibition affects
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immunotherapy response, we treated C57BL/6 mice bearing
B10F10 melanomas with anti-PD-1 antibody or isotype control
IgG. Anti-PD-1 antibody had no effect on tumor growth of
control B16F10 cells (Fig. 8a), consistent with previous stu-
dies35,43, mimicking resistance to PD-1 blockade in melanoma
immunotherapy. However, anti-PD-1 antibody signiﬁcantly
inhibited tumor growth for FTO knockdown tumors (Fig. 8a).
Next, we assessed whether the immune system is required for the
effect of FTO knockdown on anti-PD-1 blockade. In immuno-
deﬁcient NSG (severely combined immunodeﬁcient (NOD/SCID)
interleukin-2 receptor (IL-2R) gamma chain null) mice, anti-PD-
1 antibody had no effect on tumor growth in either control or
B16F10 cells with FTO knockdown (Fig. 8b). These results
indicate that the effect of FTO knockdown on melanoma
response to anti-PD-1 immunotherapy is dependent on the
immune system.
To understand the mechanism by which FTO inhibition
sensitizes melanoma to anti-PD-1 blockade, we ﬁrst analyzed
whether FTO knockdown affects T cell inﬁltration into tumors
after PD-1 blockade (Supplementary Fig. 12a). The PD-1
blockade increased CD4+ tumor-inﬁltrating lymphocyte (TIL)
numbers in B16F10 melanoma with FTO knockdown, but not in
control cells (Fig. 8c). Notably, no signiﬁcant difference was seen
in CD8+ TIL numbers in either control or FTO-knockdown cells
(Fig. 8c). We also assessed the IFNγ production of CD4+ and
CD8+ TILs on day 14 after inoculation. However, FTO knock-
down in melanoma cells did not affect the number of IFNγ-
producing CD4+ or CD8+ TILs s (Fig. 8d). Although further
investigation is necessary to establish the effect of FTO knock-
down and anti-PD-1 treatment on other immune cells and other
immune mediators, these data suggest that FTO knockdown did
not affect the inﬁltration of IFNγ-producing cytotoxic TILs.
Control
0.2% FBS + DMEM
Serum-free
HBSS
HBSS + DMEM6
R
el
at
iv
e 
m
R
N
A 
(fo
ld 
ch
an
ge
)
5
4
3
2
1
0
FTO PDCD1
a
d e
f g
N
F-
kB
 L
uc
 (fo
ld)
2.0
1.5
1.0
0.5
0.0
Control
HBSS
1.4
1.2
1
0.8
AT
G
5 
m
RN
A 
(ra
tio
)
0.6
0.4
0.2
0
sh
NC
sh
AT
G5
sh
AT
G7
shNC + control
shFTO + control
shFTO + 0.2% FBS DMEM
shFTO + HBSS
PDCD1FTO PDCD1FTO
0
1
2
3
4
m
R
N
A 
(fo
ld)
0
1
2
3
5
4
m
R
N
A 
(fo
ld)
shNC + 0.2% FBS DMEM
shNC + HBSS
siNC + control
siRELA + control
siRELA + 0.2% FBS DMEM
siRELA + HBSS
siNC + 0.2% FBS DMEM
siNC + HBSS
sh
NC
sh
AT
G5
sh
AT
G7
1.4
1.2
1
0.8
AT
G
7 
m
RN
A 
(ra
tio
)
0.6
0.4
0.2
0
sh
NC
sh
AT
G5
sh
AT
G7
Control
HBSS
FT
O
 m
RN
A 
(fo
ld)
3
2.5
2
1.5
1
0.5
0
sh
NC
sh
AT
G5
sh
AT
G7
Control
HBSS
Control
HBSS
PD
CD
1 
m
RN
A 
(fo
ld)
3
2.5
2
1.5
1
0.5
0
sh
NC
sh
AT
G5
sh
AT
G7
Control
HBSS
FTO(short) 50
50
37
37
50
20
15
20
15
37
Mr (K)
Co
ntr
ol
0.2
% 
FB
S+
DM
EM
Se
rum
-fre
e D
ME
M
HB
SS
HB
SS
+D
ME
M
PD-1(short)
FTO(long)
PD-1(long)
Lo
ng
Sh
or
t p62
LC3-I
LC3-II
LC3-I
LC3-II
GAPDH
b
m6A
Dot blot
Methylene
blue
800 ng
200 ng
50 ng
12.5 ng
Co
ntr
ol
HB
SS
Co
ntr
ol
HB
SS
c
Fig. 7 Metabolic stress induces FTO expression through NF-kB and autophagy. a qPCR analysis of FTO and PD-1 (PDCD1) mRNA levels in Mel624 cells
cultured with control medium (10% FBS DMEM), 0.2% FBS DMEM, serum-free DMEM, Hanks’ balanced salt solution containing calcium and magnesium
(HBSS), or a combination of DMEM and HBSS. b Immunoblot analysis of FTO, PD-1, p62, LC3-I/II (short and long exposure), and GAPDH in Mel624 cells
treated as in a. c m6A dot blot assays using total RNA of Mel624 cultured with control medium or HBSS. Methylene blue staining was used as a loading
control. d qPCR analysis of FTO and PD-1 (PDCD1) mRNA levels in Mel624 cells with or without knockdown of ATG5 or ATG7 and with or without
metabolic stress. e Luciferase reporter analysis of NF-κB response element in Mel624 cells as in d. f qPCR analysis of FTO and PD-1 (PDCD1) mRNA levels
in Mel624 cells with or without FTO knockdown treated with or without metabolic stress. g qPCR analysis of FTO and PD-1 (PDCD1) mRNA levels
in Mel624 cells with or without siRNA knockdown of RELA treated as in e. Data are shown as mean ± S.E. (a, d, f, g), or mean ± S.D. (e) (n≥ 3).*P < 0.05;
**P < 0.01; ***P < 0.001; Student’s t-test
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Next we analyzed the role of FTO in the response of melanoma
cells to IFNγ. First, we assessed the effect of IFNγ on m6A
regulators. IFNγ downregulated FTO in a dose-dependent
manner, but had no effect on the protein levels of other
regulators such as ALKBH5, METTL3, or METTL14 (Fig. 8e).
Consistently, IFNγ also increased m6A levels (Fig. 8f), while it
decreased PD-1 protein levels (Supplementary Fig. 12b). Next, we
investigated whether FTO knockdown sensitizes melanoma cells
to cell death induced by IFNγ. FTO knockdown did indeed
sensitize melanoma cells to IFNγ-induced growth inhibition and
cell killing (Fig. 8g, and Supplementary Fig. 12c). The converse
was also true: Overexpression of WT FTO suppressed IFNγ-
induced melanoma cell death, while overexpression of FTO
mutants had no effect (Fig. 8h). These data suggest a critical role
of FTO in the resistance of melanoma cells to IFNγ. Furthermore,
we found that overexpression of PD-1 (PDCD1), CXCR4, or
SOX10 inhibited IFNγ-induced cell death in FTO-knockdown
melanoma cells (Fig. 8i–k). Consistently, blocking IFNγ by anti-
IFNγ antibody increased tumor growth of both control and
B16F10 melanoma cells with FTO knockdown in C57BL/6 mice
(Fig. 8l). These results demonstrate that FTO inhibition enables a
response to anti-PD-1 blockade in melanoma in vivo, and to
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Fig. 8 Role of FTO in melanoma cell response to anti-PD-1 antibody in vivo or to interferon gamma (IFNγ) in vitro. a, b Tumor growth kinetics of control or
FTO-knockdown B16F10 cells in C57BL/6 mice (a) and NSG mice (b) treated with anti-PD-1 or isotype control antibody (n= 4–6). *P < 0.05. c, d Flow
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0.05. n.s., not signiﬁcant. e Immunoblot analysis of FTO, ALKBH5, METTL3, METTL14, and GAPDH in Mel624 cells treated with or without IFNγ (100 ng/
ml) for 24 h. f m6A dot blot assays using total RNA of Mel624 cells treated with or without IFNγ (100 ng/ml) for 24 h. g Apoptosis assay in Mel624 cells
with or without FTO knockdown and treatment with or without IFNγ (50 ng/ml) for 48 h. h Apoptosis assay in Mel624 cells overexpressing vector, FTO
WT, mutant 1, or mutant 2, and treated with or without IFNγ (50 ng/ml) for 48 h (n= 3). **P < 0.01, Student’s t-test. i–k Apoptosis assay in Mel624 cells
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antibody or isotype control IgG (n= 4–6). Data are shown as mean ± S.E. (a–e, and l), or mean ± S.D. (g–k) (n≥ 3). *P < 0.05; **P < 0.01; ***P < 0.001;
Student’s t-test. m Proposed model of the regulatory and functional role for FTO in melanoma pathogenesis and response to anti-PD-1 blockade
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IFNγ-induced killing in melanoma cells in vitro through
regulating melanoma cell-intrinsic PD-1, CXCR4, and SOX10.
Taken together, these results demonstrate a critical role of
melanoma cell-intrinsic FTO in promotinging melanoma resis-
tance to anti-PD-1 blockade, suggesting that FTO inhibition can
reduce resistance to anti-PD-1 therapy (Fig. 8m).
Discussion
Here we found that the obesity-associated protein FTO, also an
m6A eraser, plays an important role in melanoma (Fig. 8m). FTO
is increased in melanoma, suggesting a protumorigenic role of
FTO in melanoma. FTO increases proliferation, migration, and
invasion in melanoma cells in vitro and melanoma tumor growth
in vivo. FTO can be upregulated by metabolic stress and starva-
tion, a metabolic challenge that tumor cells are constantly facing
in vivo, suggesting that the induction of FTO serves as an
adaptive mechanism to metabolic stress in melanoma cells to
promote proliferation, invasion, and migration. At the molecular
level, FTO knockdown increases m6A enrichment in the 5′UTR
and 3′UTR regions across the whole transcriptome. FTO
knockdown increases m6A enrichment in the critical melanoma-
promoting genes including PD-1 (PDCD1), CXCR4, and SOX10,
and decreases their mRNA stability. The RNA decay of these
genes in FTO knockdown cells is mediated by the m6A reader
YTHDF2. YTHDF2 knockdown increases melanoma growth,
whereas YTHDF2 overexpression decreases it, supporting a
tumor suppressor role for YTHDF2 in melanoma. The regulation
of these three genes by FTO is mediated through m6A deme-
thylation and FTO’s demethylase activity. Lastly, FTO plays an
important role in therapeutic resistance to anti-PD-1 immu-
notherapy and cell killing by IFNγ, a critical mechanism in
immunotherapy. Overall, our ﬁndings demonstrate a crucial role
of the m6A demethylase FTO in melanoma tumorigenesis and
response to immunotherapy (Fig. 8m).
Our ﬁndings demonstrate that melanoma genes are regulated
by FTO through m6A RNA methylation. FTO has been shown to
be an RNA demethylase for m6A16 and also works on near cap
m6Am44, with opposite effects on RNA stability. FTO-mediated
m6Am demethylation was reported to promote mRNA decay44
and thus FTO could decrease transcript levels with m6Am
demethylation. However, recent studies indicated that the effect
of FTO on mRNA stability is mostly through m6A but not
m6Am45. Importantly, the cap m6Am methyltransferase PCIF1
was recently identiﬁed, and PCIF1 deletion eliminated cap m6Am
but had minimal effects on target mRNA stability46, inconsistent
with the previous report44, conﬁrming the minimal effect of cap
m6Am on mRNA stability. We found that the regulation of PD-1
(PDCD1), CXCR4, and SOX10 all appear to be partially mediated
through the latter m6A/YTHDF2 mechanism, because: (1) FTO
knockdown decreased the mRNA levels and stability of these
melanoma genes, in parallel with increased m6A enrichments; (2)
knockdown of the m6A reader YTHDF2 increased the mRNA
levels and stability of these genes, reversing the effect of FTO
knockdown; (3) knockdown of METTL3 and METTL14 reversed
the effect of FTO knockdown; (4) forced overexpression of
YTHDF2 phenocopies the effect of FTO knockdown in cell
proliferation, migration, and tumor growth. These results suggest
that m6A enrichment lead to RNA decay of these genes through a
YTHDF2-dependent mechanism in melanoma. Nevertheless, it is
still possible that FTO-regulated demethylation could have other
additional effects that remain to be uncovered.
We found that FTO plays a crucial role in metabolic pathways
in melanoma cells. First, FTO regulates PD-1 (PDCD1) expres-
sion, thus FTO-mediated demethylation promotes mTOR sig-
naling and cell growth/proliferation. Previously, FTO has been
shown to regulate nutrient sensing and mTOR47. Here we iden-
tiﬁed an epitranscriptomic mechanism by which FTO regulates
mTOR signaling through m6A-mediated tuning of the PD-1
(PDCD1) gene. Second, we found that metabolic stress and
starvation induces FTO expression in melanoma cells. This
metabolic stress-induced FTO expression requires autophagy and
NF-κB. Due to uncontrolled proliferation of tumor cells in vivo,
tumor cells likely face constant metabolic stress and lack of suf-
ﬁcient nutrient supply. It is possible that FTO induced by star-
vation promotes melanoma cell proliferation and/or survival. Our
ﬁndings suggest FTO as a critical adaptation mechanism in
melanoma cells under metabolic stress.
Anti-PD-1 checkpoint blockade therapy has demonstrated an
unprecedented anti-tumor response rate in advanced cancers,
including melanoma8,9, and reduced immune-related adverse side
effects compared to ipilimumab48. However, more than half of
such patients do not show a durable response to immunother-
apy10. Recent studies have shown that melanoma intrinsic PD-1
is one of the critical intrinsic tumor-promoting regulators in
melanoma, even in mice lacking adaptive immunity35. However,
it has been unclear how PD-1 expression is regulated in mela-
noma cells. We found that PD-1 expression is positively regulated
by FTO and m6A mRNA methylation. m6A modiﬁcation of the
melanoma cell-intrinsic PD-1 (PDCD1) gene leads to increased
mRNA decay via YTHDF2. PD-1 (PDCD1) expression is induced
via the autophagy/NF-κB/FTO axis by metabolic stress and
starvation, suggesting the FTO/PD-1 axis as a critical component
of metabolic stress adaptation. Furthermore, FTO knockdown
sensitized melanoma to anti-PD-1 blockade (Fig. 8a). Therefore,
inhibiting the FTO pathway in melanoma may provide a new
opportunity to reduce resistance to anti-PD-1 immunotherapy.
Functional intrinsic IFNγ signaling machinery is not only
critical for promoting anti-tumor immunity49, but also required
for the therapeutic response to immune checkpoint blockade11.
Consistently we found that IFNγ downregulates FTO in mela-
noma cells, and FTO mediates resistance to melanoma cell killing
by IFNγ through its m6A demethylase activity and downstream
targets PD-1 (PDCD-1), CXCR4, and SOX10. FTO over-
expression inhibits, while FTO knockdown promotes, IFNγ-
induced cell death. It is possible that, at least in part, IFNγ exerts
its cytotoxic effect by inhibiting FTO in melanoma cells. Indeed,
anti-IFNγ antibody increased melanoma tumor growth in both
control and FTO-knockdown cells in mice. Although FTO
knockdown inhibits melanoma tumor growth in both immuno-
compromised and immunocompetent hosts (Figs. 2f, 8a, b), the
response of FTO knockdown cells to anti-PD-1 requires host
adaptive immunity (Fig. 8a, b). It appears that the melanoma
intrinsic FTO pathway is not only critical for melanoma malig-
nant traits and tumorigenicity in immunocompromised hosts, but
also crucial for promoting resistance to IFNγ-induced killing
in vitro and anti-PD-1 blockade in immunocompetent hosts
in vivo. Although FTO knockdown in B16F10 increased the
number of CD4+ TILs, it did not affect the number of IFNγ-
producing CD4+ or CD8+ TILs (Fig. 8c, d). It is possible that the
intrinsic function of the FTO pathway in IFNγ resistance medi-
ated, at least in part, the effect of FTO knockdown in PD-1
blockade. Further studies are warranted to assess the full
mechanism of immune regulation by PD-1 blockade with FTO
inhibition in melanoma.
In summary, we have demonstrated that FTO inhibition sup-
presses melanoma tumorigenicity and the expression of mela-
noma cell-intrinsic genes PD-1 (PDCD1), CXCR4, and SOX10, at
least partially through YTHDF2-mediated mRNA decay. We
found that FTO inhibition enabled an anti-melanoma response to
anti-PD-1 immunotherapy in mice. Our ﬁndings may provide
new opportunities for developing improved melanoma therapies
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by inhibiting the FTO pathway in combination with anti-PD-1
immunotherapy.
Methods
Human skin tumor samples. All human specimens were studied after approval by
the University of Chicago Institutional Review Board. The human melanoma array
was obtained from US Biomax.
Cell culture. WM35, WM115, WM793, and WM3670 were kindly provided by Dr.
Meenhard Herlyn (Wistar Institute, Philadelphia, PA). Mel624, CHL-1, SK-mel30,
and B16F10 cells were purchased from ATCC or provided by the Comprehensive
Cancer Center Core Facilities at the University of Chicago. Melanoma cells were
maintained in DMEM (Dulbecco’s modiﬁed Eagle’s medium) medium (Invitrogen)
supplemented with fetal bovine serum (FBS, 10% HyClone,), penicillin (100 U/ml),
and streptomycin (100 μg/ml, Invitrogen, Carlsbad, CA). NHEM cells (Normal
Human Epidermal Melanocytes) were purchased form Lonza and cultured in 95%
air and 5% CO2 at 37 °C in NHEM deﬁned medium obtained from Lonza
according to the manufacturer’s instructions.
Lentiviral generation and infection. Lentiviral particles of shNC (Negative con-
trol) and shFTO for humans and mice were purchased from Santa Cruz Bio-
technology. pLKO.1 plasmids of shNC, shFTO, shATG5, shATG7, and shYTHDF2
(human) were obtained from Sigma. pLenti plasmids of overexpression control
(mGFP) and overexpression of PDCD1(mGFP-PDCD1), CXCR4, and SOX10 for
humans were obtained from Origene (Origene, Rockville, MD). Lentivirus was
produced by co-transfection into HEK-293T cells with lentiviral vectors in com-
bination with the pCMVdelta8.2 packaging vectorand pVSV-G envelope vector
using GenJet Plus DNA In Vitro Transfection Reagent (Signagen). Virus-
containing supernatants were collected 24–48 h after transfection and used to
infect recipients. Target cells were infected in the presence of Polybrene (8 μg/ml)
(Sigma-Aldrich) and selected with puromycin (Santa Cruz Biotechnology, 1 μg/ml)
for 6 days.
Luciferase reporter assays. Using GenJet Plus DNA In Vitro Transfection
Reagent (Signagen), cells were transfected with pGL3 NF-κB-Luc (1 μg) and pRL-
TK (0.025 μg), as a control for transfection efﬁciency (Promega), according to the
manufacturer’s instructions. Luciferase reporter assays (Promega) were carried out
according to the manufacturer’s instructions.
siRNA transfection. Using GenMute siRNA Transfection Reagent (Signagen),
cells were transfected with siRNA (Dharmacon), targeting negative control (NC)
METTL3, METTL14, YTHDF1, YTHDF2, and YTHDF3, according to the man-
ufacturer’s instructions.
Quantitative real-time PCR (qPCR). qPCR assays were carried out using a CFX
Connect real-time system (Bio-Rad, Hercules, CA) with Bio-Rad iQ SYBR Green
Supermix (Bio-Rad). The threshold cycle number (CQ) was analyzed in triplicate
for each sample. The CQ values for ANGPTL2, RAB40B, CTSV, RBBP9, NOP16,
FCMR, PDCD1, CD274, CD47, CDKN1A, METTL3, METTL14, FTO, ALKBH5,
YTHDF1, YTHDF2, YTHDF3, ATG5, ATG7, GAPDH, β-actin, and HPRT1 were
normalized against HPRT1, GAPDH, or β-actin. The primer sequences used for
qRT-PCR are shown in Supplementary Table 1.
Flow cytometric analysis of apoptosis. Apopotosis was analyzed using the
annexin V-FITC apoptosis detection kit (eBioscience), following the manu-
facturer’s instructions. Cell were then by a BD FACSCalibur ﬂow cytometer (BD
Biosciences). For cells viability assay in cells in suspension, poly-hydroxyethyl
methacrylate (poly-HEMA) plates were used toculture cells in suspension. A
solution of poly-HEMA (Sigma–Aldrich, St. Louis, MO) mixed in ethanol was
poured onto polystyrene bacteriological dishes. After the poly-HEMA had dried,
the same procedure was repeated once followed by extensive washing with phos-
phate buffered saline (PBS).
Migration and invasion assay. For migration and invasion analysis, cell (5 × 104)
suspension (150 μl of serum-free medium) were seeded onto 8-mm Pore Transwell
Inserts (Corning) coated with Matrigel for invasion assay, or without Matrigel for
migration assay. Lower chambers were ﬁlled with complete medium (900 μl). Cells
on the Transwell Inserts were then ﬁxed with paraformaldehyde/PBS (4%) for 30
min. Next, ﬁxed cells were stained with hematoxylin solution (Sigma-Aldrich) for
1 h. Then microphotograms of the cells migrated onto the lower side of the ﬁlter
were imaged using a microscope. From the microphotograms, cells that migrated
or invaded onto the lower side of the ﬁlter were manually counted. Cell numbers
were quantiﬁed from ten randomly selected ﬁelds with the same area (500 μm×
500 μm) per Transwell insert.
Soft agar colony formation and 3D on-top culture in matrigel. For soft agar
assay, in a 35-mm petri dishes, 3000 cells were resuspended in 0.3% Agarose-low
gelling temperature (Sigma-Aldrich) in DMEM with FBS (10%) and layered over 1
ml 0.5% agar in DMEM with 10% FBS. Colonies with more than eight cells were
counted. For 3D on-top culture, 4-well glass chamber slides (BD Biosciences) were
coated with 120 ml of growth factor reduced Matrigel per well; 5000 cells were
seeded per well in DMEM with fetal bovine serum (10%) and Matrigel (10%).
Immunoﬂuorescence and immunohistochemistry. For immunoﬂuorescence
analysis, cells were ﬁrst ﬁxed with paraformaldehyde/PBS (4%) for 30 min, fol-
lowed by permeabilized in Triton X-100/PBS (0.5%) for 20 min. Next cells were
washed with PBS, blocked with PBS supplemented with 2% normal goat serum
(Invitrogen) for 30 min, and stained for actin ﬁlaments with rhodamine-labeled
phalloidin (Invitrogen, Carlsbad, CA). Then cells were washed three times with
Triton X-100/TBS (0.1%) for 10 min and ﬁxed in Prolong Gold Antifade with
DAPI (Invitrogen), followed by observation under a ﬂuorescence microscope
(Olympus IX71).
For Human Melanoma Tissue Microarray staining, melanoma tissue array
slides were obtained from US Biomax (Rockville, MD). After removing the
blocking solution (3% albumin from chicken egg white (Sigma-Aldrich) in PBS),
tissue array slides were incubated at 4 °C with primary rabbit anti-FTO, goat anti-
PD-1, or mouse anti-MART1 for 18 h. After removing the primary antibodies,
slides were washed with PBS solution with 0.025% TritonX-100. Tissue array slides
were then incubated at room temperature with Alexa Fluor 594-conjugated
secondary rabbit IgG (Jackson ImmunoResearch), Alexa Fluor 488-conjugated
secondary mouse IgG (Jackson ImmunoResearch), and Alexa Fluor 405-conjugated
secondary goat IgG (Jackson ImmunoResearch), then washed with TritonX-100
(0.025% in PBS), and mounted with Prolong Gold Antifade with DAPI
(Invitrogen) forcell nucleus counterstaining for FTO/MART1 staining, or with
Fluoromount Mounting Medium (Sigma-Aldrich) for FTO/PD-1/MART1 staining.
Two investigators independently scored the immunoﬂuorescence intensity and
staining blindly, as 3 (strong), 2 (medium), 1 (weak), and 0 (negative). ImageJ
(NIH) was also used for analyzing melanoma cells and tissue arrays. Areas with the
same size were selected. The intensity of a selected area was measured followed by
background subtraction to calculate mean pixel density. Stained samples were
analyzed using a ﬂuorescence microscope (Olympus IX71)
Antibodies used are as follows: anti-FTO (Abcam, ab126605, 1:100); anti-
MART1 (NOVUS, NBP 2–15197, 1:100); Rhodamin-phalloidin (Life technologies,
R415, 1:100); anti-PD-1 (R&D Systems, Cat# AF1086 Minneapolis, 1:100).
Cell proliferation assay. Cell proliferation was assessed using the Cell Counting
Kit-8 (CCK-8) (Sigma-Aldrich, St. Louis, MO) following the manufacturer’s
protocol.
Immunoblotting. Cell lysates were obtained using RIPA buffer (Pierce) containing
inhibitors for proteases and phosphatases. Protein abundance were then analyzed
by SDS-PAGE, and transferring onto nitrocellulose membranes followed by
immunoblotting. Antibodies used are as follows:
Anti-ALKBH5 (Millipore Co., ABE 1013, 1:2000); anti-Beta-actin (Santa Cruz,
SC-47778, 1:5000); anti-CXCR4 (Santa Cruz, SC-53534, 1:200); anti-CXCR4
(Novusbio, NBP1-77067SS, 1:5000); FTO (Santa Cruz, SC-271713, 1:200); GAPDH
(Santa Cruz, SC-47724, 1:5000); GFP (Cell Signaling Technology, 2555S, 1:1000);
LC3B (Cell Signaling Technology, 3868S, 1:1000); METTL14 (Millipore Co., ABE
1338, 1:1000); METTL3 (Proteintech, 15073-I-AP, 1:1000); p62 (Progen Biotechnik
GmbH, GP62-C, 1:10,000); p70s6K (Cell Signaling Technology, 2708S, 1:2000);
PD-1 (Proteintech, 66220-I-Ig, 1:5000); p-p70s6K (Cell Signaling Technology,
9234S, 1:1000); and SOX10 (Santa Cruz, SC-365692, 1:2000). The unprocessed
blots are provided in Source Data.
Mouse tumorigenesis and treatment. All of the animal procedures used were
approved by the institutional animal care and use committee at the University of
Chicago. Nude mice were purchased from Harlan Sprague-Dawley. C57BL/6 mice
were obtained from Envigo. NSG (severely combined immunodeﬁcient (NOD/
SCID) interleukin-2 receptor (IL-2R) gamma chain null) mice were obtained from
Jackson Laboratory. For xenograft experiments, one million cells were injected
subcutaneously into the right ﬂanks of 6-week-old female nude or C57BL/6 mice.
Tumor growth was monitored and measured weekly by a caliper, and tumor
volume was calculated using the formula, Tumor volume (mm3)= d2 ×D/2, where
d and D are the shortest and the longest diameters, respectively. For treatment with
anti-PD-1 antibody (BioXCell, clone RMP1-14) or isotype control IgG antibody
(BioXCell, clone 2A3), B16F10 melanoma cells (5 × 105) were inoculated sub-
cutaneously into C57BL/6 or NSG mice. When the tumors reached a volume of
80–100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200
μg/mouse) by i.p. injection, every other day for three times. For IFNγ blockade
treatment, C57BL/6 mice were treated with anti-IFNγ antibody (BioXcell, Clone
XMG1.2) or isotype control IgG (BioXcell, Clone HRPN) (250 μg/mouse) every
other day after tumor cell inoculation50,51.
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Analysis of tumor inﬁltrating lymphocytes (TILs). Tumor tissue from B16F10
tumor-bearing mice (Day 14 after tumor cell inoculation) was dissociated by
digestion with 2.5 mg/ml collagenase type IV (Worthington Biochemical,
LS004188) and 100 μg/ml DNAse (Sigma-Aldrich, DN25) in RPMI 1640 with 5%
FBS for 45 min at 37 °C. After digestion, tumor tissue was passed through 70-μm
ﬁlters and mononuclear cells collected on the interface fraction between 40 and
80% per cell. Live cells (Zombie NIR negative) were gated using Zombie-violet
(Catalog: 423105) staining. Next cells were gated using FSC-A and FSC-H to
exclude doublets. Lymphocytes were gated on SSC-A and FSC-A. CD4+ and CD8+
TILs were gated on CD45+CD3+ cells. Gating strategies are shown in Supple-
mentary Fig. 12a. The following mAbs recognizing the indicated antigens were
used: FITC-anti-CD3 (Clone: 17A2, Catalog: 100204, 1:100), BV605-anti-CD4
(Clone: GK1.5, Catalog: 100451, 1:200), PE-Cy7-anti-CD8 (Clone: 53–6.7, Catalog:
100722, 1:200), PerCP-Cy5.5-anti-CD45 (Clone: 30-F11, Catalog: 103129, 1:400),
Zombie-violet (Catalog: 423105), and APC-anti-IFNG (Clone: XMG1.2, Catalog:
505810, 1:100) (BioLegend). For assessment of IFNγ, cells were stimulated with 50
ng/ml phorbol 12-myristate 13-acetate (Sigma-Aldrich, P8139) and 1 μg/ml
ionomycin (Fisher Scientiﬁc, BP25271) in the presence of Brefeldin A (BioLegend,
420601) for 4 h. After incubation, cells were then ﬁxed. After surface staining, cell
werepermeabilized using the BioLegend Kit (Catalog: 421002) and. Data were
analyzed using FlowJo (version 10.5.3; FlowJo LLC).
m6A dot blot assay. Total RNA was extracted using an RNeasy plus Mini Kit
(QIAGEN, Hilden, Germany), following the manufacturer’s protocol. For mRNA
isolation,ﬁrst total RNA was extracted using an RNeasy mini kit with DNase I on-
column digestion, followed by polyadenylated RNA extraction using a Dynabeads
mRNA Puriﬁcation Kit (Life technology, Carlsbad, CA). Then mRNA was con-
centrated with an RNA Clean & Concentrator-5 kit (Zymo Research, Irvine, CA).
Brieﬂy, RNA samples were loaded onto Amersham Hybond-N+membrane
(GE Healthcare, Chicago, IL) and crosslinked to the membrane with UV radiation.
Then the membrane was blocked with 5% nonfat dry milk (in 1X PBST) for 1–2 h,
incubated with a speciﬁc anti-m6A antibody (Synaptic Systems, 202003, 1:2000)
overnight at 4 °C followed by HRP-conjugated anti-rabbit IgG (Cell Signaling
Technology) for 1 h at room temperature, and then developed with Thermo ECL
SuperSignal Western Blotting Detection Reagent (Thermo Fisher Scientiﬁc,
Waltham, MA).
mRNA stability assay. A transcriptional inhibitor, actinomycin D (2 μM), inhibits
mRNA transcription. Each sample was harvested at 0, 3, and 6 h after treatment
with actinomycin D. Total RNA was isolated with an RNeasy plus mini kit
(QIAGEN). The HPRT1 housekeeping gene was used as a loading control. HPRT1
mRNA does not contain m6A modiﬁcations, is not bound by YTHDF2, and is
rarely affected by actinomycin D treatment23,52.
m6A IP. 100–150 μg total RNA was extracted from cells using TRIzol following the
manufacturer’s protocol. mRNA was puriﬁed using a Dynabeads mRNA DIRECT
Kit following the manufacturer’s protocols. One microgram mRNA was sonicated
to ∼200 nt, 5% of fragmented mRNA was saved as input, and m6A containing
mRNA fragments were enriched with an EpiMark N6-Methyladenosine Enrich-
ment Kit following the manufacturer’s protocols. Finally, together with the input,
IP RNA was extracted using RNA Clean and Concentrator (Zymo Research),
followed by library preparation using the TruSeq stranded mRNA sample pre-
paration kit (Illumina).
Sequencing data analysis. General pre-processing of reads: sequencing were
performed using Illumina Hiseq4000 with single end 80 bp read length. The
adapters were removed by using cutadapt for m6A-seq, reads were aligned to the
reference genome (hg38) in Tophat v2.0.14 using the parameter -g 1–library-type
= fr-ﬁrststrand. RefSeq Gene structure annotations were obtained from the UCSC
Table Browser. If a gene had multiple isoforms, the longest isoform was used. In
order to eliminate the interference caused by introns in peak calling, aligned reads
were extended to 150 bp (average fragment size) and converted from genome-
based coordinates to isoform-based coordinates. The method used for peak calling
was adopted from published work with modiﬁcations17. For calling m6A peaks, a
gene’s longest isoform was scanned using a sliding window (100 bp) with a step of
10 bp. To mimimize bias from potential inaccuracy in gene structure annotation
and/or the longest isoform, windows with read counts of less than 1/20 of the top
window in both m6A-IP and the input were excluded. The read counts in each
window for each gene were normalized by the median count of all windows forthe
gene. The differential windows between IP and input samples were identiﬁed using
a Fisher exact test. If the FDR < 0.01 and log2(Enrichment Score) ≥ 1, the window
was considered as positive. Overlapping positive windows were merged. To obtain
the enrichment score of each peak (or window), the following four numbers were
calculated: (1) read counts of the IP samples in the current peak/window, (2)
median read counts of the IP sample in all 100 bp windows on the current mRNA,
(3) read counts of the input sample in the current peak/window, and (4) median
read counts of the input sample in all 100 bp windows on the current mRNA. For
each window, the enrichment score was calculated as (a × d)/(b × c).
Gene-speciﬁc m6A qPCR. Real-time qPCR was performed to assess the relative
abundance of the selected mRNA in m6A antibody IP samples and input samples.
Brieﬂy, total RNA was isolated with an RNeasy mini kit. With 500 ng RNA kept as
an input sample, the remaining RNA was used for m6A-immunoprecipitation.
Hundred microgram of RNA was diluted into 500 μl IP buffer (150 mM NaCl, 0.1%
NP-40, 10 mM Tris, pH 7.4, 100 U RNase inhibitor) and incubated with m6A
antibody (Synaptic Systems, Goettingen, Germany). The mixture was rotated at 4 °
C for 2 h, then Dynabeads® Protein A (Thermo Fisher Scientiﬁc, Waltham, MA)
coated with BSA was added into the solution and rotated for an additional 2 h at 4 °
C. After washing by IP buffer with RNase inhibitors four times, the m6A IP portion
was eluted with elution buffer (5 mM Tris-HCL pH 7.5, 1 mM EDTA pH 8.0,
0.05% SDS, and 4.2 μl Proteinase K (20 mg/ml)18. The ﬁnal eluted mRNA was
concentrated with an RNA Clean & Concentrator-5 kit (Zymo Research, Irvine,
CA). The same amount of the concentrated IP RNA or input RNA from each
sample was used for the cDNA library. The mRNA expression was determined by
the number of ampliﬁcation cycles (Cq). The relative m6A levels in genes were
calculated by the m6A levels (m6A IP) normalized using the expression of each
gene (Input).
Microarray analysis. RNA was extracted from Mel624 cells with or without FTO
knockdown with the RNeasy Mini Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. Total RNA concentration and purity were determined
with NanoDrop (Thermo Scientiﬁc, Waltham, Mass), and total RNA integrity was
conﬁrmed with the Agilent Bioanalyzer (Agilent Technologies, Santa Clara, Calif).
The RNA samples were processed with the HumanHT-12 v4.0 Gene Expression
BeadChip microarray (Illumina) at the Functional Genomics Core Facility of the
University of Chicago. The data have been deposited in the GEO repository with
the accession numbers GSE128961.
Statistical analyses. Statistical analyses were carried out using Prism 6 and 7
(GraphPad). Data were obtained from at least three independent experiments and
for statistical signiﬁcance were analyzed using Student’s t-test or Mann–Whitney
U-test. P < 0.05 was considered statistically signiﬁcant.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
m6A IP sequencing and RNA sequencing data are accessible at the GEO repository,
under accession number GSE112902. Microarray data are accessible at the GEO
repository, under accession number GSE128961. Other data from this study are available
from the corresponding author upon request. The source data of immunoblots are
provided as a Source Data ﬁle.
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